Summary
Summary

Congenital myasthenic syndromes are a heterogeneous group
AChR-deficiency patients. 
Introduction
Nicotinic acetylcholine receptors (AChRs) are highly 1992). Within the junctional region, utrophin is more precisely co-localized with AChRs than are β-spectrin and dystrophin concentrated in the plasma membrane of vertebrate skeletal (Bewick et al., 1992) . Furthermore utrophin, but not β-muscle fibres at the neuromuscular junction where they spectrin or dystrophin, is present at AChR clusters at the mediate the response of the muscle to neurotransmitter earliest stages of neuromuscular junction formation (Noakes (Salpeter, 1987) . In some human disorders, the local density of et al., 1993) and is co-localized with the AChRs throughout AChRs is greatly reduced, leading to impaired neuromuscular postnatal development (Bewick et al., 1996) . While these transmission and muscle weakness. The best known of these close spatial and developmental associations with AChRs conditions is acquired autoimmune myasthenia gravis, in suggest a role for utrophin at the neuromuscular junction, which the binding of autoantibodies to AChRs leads to loss recent studies of utrophin-deficient mice indicate that utrophin of functional receptors. In a second, more heterogeneous, is not essential for normal AChR localization (Deconinck group of conditions, AChR deficiency is present from birth et al., 1997; Grady et al., 1997) . or early infancy (Morgan-Hughes et al., 1981; Another cytoplasmic protein, rapsyn (long known as the et al., 1981) . In most of the latter group, there is at least '43 K protein'), is also closely co-localized with AChRs circumstantial evidence that the condition is inherited but in (Froehner et al., 1981; Flucher and Daniels, 1989) . Rapsyn no case has either the causative genetic defect or the cellular has been shown to cause clustering of AChRs (Froehner, and molecular pathology of the events leading to the AChR 1993) and in the absence of rapsyn, neuromuscular junctions deficiency been identified. These various cases of congenital fail to develop (Gautam et al., 1995) , implying a crucial role AChR deficiency form a subset of the group of inherited for rapsyn in neuromuscular junction formation. There is conditions in which neuromusuclar transmission is impaired, some evidence that rapsyn can bind to β-dystroglycan (Apel known as congenital myasthenic syndromes (for recent et al., 1995) , suggesting the possibility of links between review, see Vincent et al., 1997) .
AChRs and utrophin via rapsyn and β-dystroglycan, that may There is currently much interest in the possibility that one contribute to AChR clustering at the neuromuscular junction. of the factors maintaining the locally high AChR
We report here studies of four patients in whom AChR concentration at the neuromuscular junction is an interaction deficiency has been established by electrophysiological and of the AChRs with the underlying membrane cytoskeleton, ligand-binding studies. In each of them, morphological studies possibly via intermediate linking proteins (Bloch and showed an elongation of the neuromuscular junction and Pumplin, 1988; Hall and Sanes, 1993) . Spectrin is present in some reduction of postsynaptic folding. Immunocytochemical the membrane skeleton of many cells where one of its studies were made of several proteins normally associated functions is believed to be the localization of transmembrane with the postsynaptic membrane, including rapsyn, β-spectrin, ion channels (Srinivasan et al., 1988; Froehner, 1993) . Several dystrophin, utrophin and β-dystroglycan to see if their proteins related in structure to spectrin are present in skeletal abundance or distribution was altered at the neuromuscular muscle fibres including forms of β-spectrin itself (Bloch and junction in AChR-deficiency patients. For comparison, similar Morrow, 1989; Bewick et al., 1992) , dystrophin (Hoffman immunocytochemical studies were also made of patients with and Kunkel, 1989) and the dystrophin-related protein utrophin myasthenia gravis in whom AChRs are deficient as a result (Nguyen thi Man et al., 1991; Ohlendieck et al., 1991;  of autoantibody binding. Bewick et al., 1992) . Neither β-spectrin nor dystrophin seem Some of these results have already been published in likely to determine AChR distribution since within the abstract form (Fawcett et al., 1994; Slater et al., 1994) . neuromuscular junction, both these proteins appear to be most concentrated in the depths of the postsynaptic folds (Sealock et al., 1991; Bewick et al., 1992) et al., 1989) . It possesses similar N-terminal binding (Patients AChRD 2-4). In each case, the patient's parents sites for spectrin and C-terminal binding sites for β-were first or second cousins and in two cases (Patients dystroglycan, the integral membrane protein that is likely to AChRD 1 and AChRD 4), there were similarly affected be responsible for utrophin binding at the cell surface.
siblings. Clinical features are listed in Table 1 . Generalized Like dystrophin, utrophin is highly concentrated at the muscle weakness was present in all patients, with weakness neuromuscular junction but differs in being absent from the of eye and facial muscles prominent. In all cases, EMG non-junctional surface of normal muscle fibres (Nguyen thi studies showed impairment of neuromuscular transmission (significant decrement of responses to repetitive stimulation, Man et al., 1991; Ohlendieck et al., 1991; Bewick et al., Vincent et al., 1997) . Strength was increased in from the intercostal muscles (Patients AChRD 2-4, Patients all patients with anticholinesterase treatment. No medication MG 1-3, Control 3). In all cases, the methods were essentially was given on the day of the biopsy procedure. After informed as described previously (Vincent et al., 1981; , consent was obtained, biopsy samples were taken from either 1992; Plomp et al., 1995) . the vastus lateralis (Patient AChRD 1) or the external intercostal muscle (Patients AChRD 2-4). Approval of the local Ethical Committee for these studies was obtained in both Newcastle and Oxford.
Electrophysiology
Biopsy samples were maintained in well-gassed (5% CO 2 and 95% O 2 ) bathing fluid (Liley, 1956 ) at room temperature while functioning nerve-muscle preparations were isolated Myasthenia gravis by dissection. These preparations were mounted in a recording Immunocytochemical studies were also made of frozen biopsy chamber at 21-24°C and were continuously perfused with samples of intercostal muscles from three patients with fresh bathing fluid. acquired autoimmune myasthenia gravis, aged 22-42 years Intracellular recordings from vastus lateralis (Patient (Patients MG 1-3). One of these was from Oxford (Patient AChRD 1) were made and analysed as described previously MG 1) and the other two from Groningen (Patients MG 2 and 3). All cases had elevated serum levels of anti-AChR (Slater et al., 1992) . Briefly, the muscle fibres were cut to a antibodies and responded positively to anticholinesterase length of~2 cm which depolarized them enough to block treatment. In each case, the biopsy sample was removed muscle fibre action potential generation and contraction. In during an operation to remove a hyperplastic thymus. All most cases, two microelectrodes were inserted in each muscle patients had been receiving anticholinesterase treatment prior fibre, one used to pass current to hyperpolarize the cell at a to the operation. membrane potential between -60 and -80 mV in current clamp mode, or for two-electrode voltage clamping, and the other to record the membrane potential. Spontaneous miniature endplate potentials (MEPPs) and miniature endplate
Control material
currents (MEPCs), and nerve-evoked (1 Hz) endplate Data from four individual control subjects are reported here. potentials (EPPs) and endplate currents (EPCs), were recorded Subjects Control 1 and Control 2 (female aged 37 and male on magnetic tape for subsequent analysis. From these aged 38, both suffering from muscle pain of unknown origin: recordings, the peak amplitude, rise time (10-90%) and vastus lateralis biopsies) were studied in Newcastle and have exponential decay time constant of the synaptic events were been described in Slater et al. (1992) (subjects 37 and 38 in measured. The quantal content of the nerve-evoked response that study). Subject Control 3 (female aged 28 years (stimulation at 1 Hz) was estimated from MEPC and EPC undergoing surgical correction for scoliosis: intercostal records, using the 'direct' method (McLachlan, 1978) . All muscle biopsy) was studied in Oxford. Finally, some studies values for the amplitude of synaptic events have been were made in Newcastle of a sample of medial gastrocnemius normalized to a resting membrane potential of -80 mV. taken from a leg amputated from a 58-year-old male patient Similar procedures were used for analysis of intercostal with chronic vascular disease (Control 4). muscle samples (Patients AChRD 2-4) but bundles of intact In addition, some averaged control data which had been muscle fibres were used and voltage clamping was not obtained in previous studies by the groups in Newcastle performed. The response to nerve stimulation, in muscle (Slater et al., 1992) and Oxford (Ito et al., 1978; Vincent et al., 1981; Shillito et al., 1993) are also cited for comparison.
fibres which had become depolarized as a result of electrode penetration (Maselli et al., 1991) , was studied in only one containing 3% BSA (bovine serum albumin) and 100 mM lysine for 1 h. The following antibodies were used; of these (Patient AChRD 4).
α-Bungarotoxin binding
Primary antibodies Vincent et al., 1981 Vincent et al., ). et al., 1991 , used at a dilution of 1/1000. After being washed well, the muscles were fixed and reacted to demonstrate acetylcholinesterase activity at the AChR ε-subunit. A rabbit antiserum raised against two neuromuscular junctions. Regions of small bundles~0.5 mm synthetic peptides spanning amino acids ε341-413 (Beeson long containing~5-20 neuromuscular junctions, and adjacent et al., 1996) , used at a dilution of 1/500. regions of the same length free of neuromuscular junctions, were cut out and the radioactivity within them counted in a γ-counter to determine the total number of AChRs present AChE. A rabbit antiserum raised against rat brain at the neuromuscular junctions. The samples were then cholinesterase (Marsh et al., 1984) used at a dilution of 1/500. mounted on microscope slides and the number of neuromuscular junctions counted. From these counts, the Rapsyn. A new polyclonal rabbit serum, raised against number of AChRs per neuromuscular junction was calculated.
recombinant rat 43 kD protein (using a construct provided Details of the method are given elsewhere (Vincent et al., by Dr J. Sanes), used at a dilution of 1/100. 1981; Slater et al., 1992) .
The distribution of AChRs was studied after labelling
Utrophin. Three monoclonal antibodies were used, all at muscles in tetramethylrhodamine isothiocyanate (TMRITC)-a dilution of 1/10: DRP1/12B6 raised against a peptide α-bungarotoxin, 0.6 µM, in bathing medium for 4 h at room representing the last 11 amino acids of the dystrophin-related temperature. Preparations were viewed with a fluorescence Duchenne muscular dystrophy-like (DMDL) gene sequence microscope and images obtained as described below.
published by Tinsley et al. (1992 ) (Bewick et al., 1992 ; MANCHO7 (a kind gift of Dr G. E. Morris), raised against a bacterial fusion protein containing the last 329 amino acids
Anatomical studies
of the utrophin/DMDL sequence (Nguyen thi Man et al., Samples were studied with the light microscope after 1991); and DRP3/20C5 (equivalent to NCL-DRP2, paraformaldehyde fixation (4% for 1.5 h) and histochemical Novocastra, UK), a new antibody raised against a fusion demonstration of acetylcholinesterase activity (Karnovsky protein provided by Professor K. E. Davies, containing the and Roots, 1964). Some samples were also impregnated with first 261 amino acids of the published DMDL sequence silver to reveal the pattern of intramuscular and terminal (Tinsley et al., 1992) . The latter antibody labels a single nerve branching. The functional terminal innervation ratio band at~400 kDa in Western blots of lung, and in normal (Coërs and Woolf, 1959) was determined as previously muscle fibres labels neuromuscular junctions and described (Slater et al., 1992) . myotendinous junctions but not the nonjunctional surface. Ultrastructural studies were made of neuromuscular junctions in samples of tissue fixed in glutaraldehyde (2.5% Dystrophin. Two monoclonal antibodies previously for 2 h) and embedded in Araldite resin. Morphometric described, one against the rod domain [Dy4/6D3; Nicholson analyses of neuromuscular junctions in these samples were et al. (1989) , used neat] and the other against an epitope at made essentially as described previously (Slater et al., 1992) .
the C-terminal [Dy8/6C5; Nicholson et al. (1992) , used at a The key features measured were the extent of coverage of dilution of 1/100]. the specialized postsynaptic surface by the nerve terminal ('Occupancy'), the increase in membrane area due to folding ('Fold Index') and the mean number of fold openings per β-dystroglycan. A monoclonal antibody (43DAG/8D5) micrometre of postsynaptic membrane in contact with the raised against a synthetic peptide containing 15 of the nerve ('Fold Frequency').
last 16 amino acids at the C-terminus of the published β-dystroglycan sequence (Bewick et al., 1993) used at a dilution of 1/100.
Immunolabelling
All labelling was done on 6 µm-thick unfixed sections of β-spectrin. A monoclonal antibody (RBC2/5C4) raised against human erythrocyte ghosts (Bewick et al., 1992) muscle frozen in isopentane cooled in liquid nitrogen. All antibodies were applied in PBS (phosphate buffered saline) used neat.
Secondary antibodies
TMRITC-conjugated rabbit anti mouse immunoglobulin (DAKO; 1/100) and TMRITC-conjugated swine anti rabbit immunoglobulin (DAKO; 1/100) were used as second antibodies.
Identification of neuromuscular junctions
Because the patients had a greatly reduced number of AChRs, fluorescent conjugates of α-bungarotoxin could not be used to identify neuromuscular junctions in double labelling experiments. We therefore used fluorescein isothiocyanate (FITC)-labelled Dolichos biflorus agglutinin (FITC-DBA; Sigma) to mark neuromuscular junctions (Sanes and Cheney, 1982) . For this purpose, the FITC-DBA (5 µg/ml) was added to the secondary antibody solution. selectivity. Images were recorded on Ilford HP-5 film using an exposure time of 15 s for TMRITC and 1 min for FITC.
To estimate the intensity of antibody labelling, the FITC-
Scoring of labelling
DBA image was used to create a mask defining the region All labelled preparations were examined and the apparent of most intense labelling. This mask was then applied to the labelling intensity at the neuromuscular junction given a TMRITC-antibody image and the total intensity within the score by an experienced observer. The scores used were '-' area defined by the mask was calculated. All intensity values for no labelling, 'ϩ' for weak labelling, 'ϩϩ' for intermediate were expressed as grey levels per second of exposure time. labelling and 'ϩϩϩ' for strong labelling. These scores have This value was divided by the area of the mask to give the been used in compiling Table 5 . mean intensity of labelling per unit area within the region defined by the mask. A background value, determined by applying the same procedure to sections in which the primary
Quantification of labelling intensity
antibody had been omitted, was subtracted from all values An objective measure of the intensity of fluorescent labelling obtained from sections labelled with a primary antibody, to by antibodies to utrophin and dystrophin on sections was give the net labelling intensity. obtained using a cooled charge coupled device camera For each of Patients 9-13, neuromuscular junctions were imaging system with 12 bit intensity resolution (ASTROMED analysed for each antibody studied. 4100, Imager 2ϩ software, Astromed Ltd, Cambridge, UK). For all the images obtained, the camera was operating within a range where the recorded pixel intensity was linearly dependent on the exposure time. Primary antibodies were Statistics used at or near saturating concentration as determined by Data are expressed in the tables as means Ϯ standard suitable dilution experiments (data not shown). Sections deviations together with the number of observations averaged. were labelled with both FITC-DBA and TMRITC-secondary Data from individual patients, usually means of values from antibody. Images were obtained with a ϫ50 water immersion a number of neuromuscular junctions, have been compared objective on a M2B microscope (Micro Instruments, UK) with mean values obtained from a number of control subjects. using Nikon filter blocks G-1B (TMRITC) and B-2H (FITC),
In these cases, values from individual patients are considered with an additional narrow band-pass emission filter (Leitz significantly different from the control means when they lie 525/20 nm) to improve FITC selectivity, and stored on optical disc for subsequent analysis.
Ͼ2 SDs from those means. Ito et al., 1978) . Intracellular recordings from an isolated vastus lateralis These findings show that in each of the four patients nerve-muscle preparation from Patient AChRD 1 revealed studied, the effect of a single quantum of ACh was greatly that the amplitude of the EPPs and EPCs evoked by reduced. Ligand-binding studies were made to test the stimulation of the nerve at 1 Hz, was significantly less than hypothesis that this results from reduced numbers of AChRs. normal (41% and 30% of controls, respectively; see Fig. 1 and Table 2 neuromuscular junction was significantly less in all four The reduction in amplitude of the nerve-evoked response AChR-deficiency patients than in comparable controls (mean could be due to reduced transmitter output or to reduced value 16.5 % of that in controls; Table 2 ). transmitter action. The estimated mean number of ACh quanta released from individual motor axon terminals in Patient AChRD 1 in response to a single nerve impulse
TMRITC-α-bungarotoxin
(quantal content) was not significantly different from that in Normal neuromuscular junctions are easy to detect in the control biopsy samples (Table 2) . Furthermore, the frequency fluorescence microscope after labelling of AChRs with of MEPPs was greatly increased at most neuromuscular TMRITC-α-bungarotoxin. In contrast, it was not possible junctions following stimulation at 50 Hz for 10 s, implying to locate neuromuscular junctions in any of the samples from that the events leading to activity-mediated potentiation of the AChR-deficiency patients using this technique. Doubletransmitter release were intact. On the other hand, the labelling experiments, in which FITC-DBA was used to amplitude of the MEPPs was greatly reduced, while that of identify the neuromuscular junctions in frozen sections, MEPCs (~30% of control values) was too small to allow confirmed that TMRITC-α-bungarotoxin labelling of accurate measurement.
identified neuromuscular junctions was undetectable (Fig. 2) . In a second patient (AChRD 4), a nerve-muscle preparation was prepared from the intercostal muscle. The EPP amplitude was significantly less (20%) than at neuromuscular junctions of control subjects (Table 2) . Quantal content was near
Immunocytochemistry
Reduced α-bungarotoxin binding could be due to an normal but MEPP amplitude (0.26 mV) was significantly less than the normal value (0.68 mV; Ito et al., 1978) , the abnormality of AChR structure that prevented normal α-bungarotoxin binding, or to a decreased abundance of AChRs. recorded value almost certainly being a substantial overestimate since many MEPPs with amplitudes of Ͻ0.1 mV To test the latter possibility, antibody labelling of AChRs was studied using immunocytochemistry (Fig. 2) . In all four would not have been detected.
In a further two patients (AChRD 2 and 3), AChR-deficiency patients labelling with antibodies against the α-and ε-subunits of the AChRs, which is strong at electrophysiological studies were limited to recordings of normal neuromuscular junctions, was undetectable or only (Fig. 4) . Morphometric analysis indicated that the size of the individual boutons of the nerve terminals and the extent of barely detectable. This was later confirmed by quantification of the intensity of fluorescent labelling (see below). the postsynaptic surface covered by them ('Occupancy') was normal (Table 4 ). In contrast, the extent of postsynaptic These findings, taken together with the electrophysiology and the α-bungarotoxin binding studies, demonstrate a folding, as reflected both by the total amount of membrane in the folds ('Fold Index') and by the number of fold openings profound deficiency of AChRs at the neuromuscular junctions of each of the four AChR-deficiency patients.
per µm of postsynaptic membrane ('Fold Frequency') was less than in comparable controls (compare AChR-deficiency with Control neuromuscular junctions in Fig. 4 and Table 4 ). This reduction was statistically significant when values from
Anatomical studies
Anatomical studies were made at both the light and electron Patient AChRD 1 were compared with average values from control vastus lateralis neuromuscular junctions. Values microscope level of samples from each of the four AChRdeficiency patients and from suitable controls.
from all three AChR-deficiency patients in which the intercostal muscle was studied (AChRD 2-4) were also significantly less (t test, P Ͻ 0.05) than those from the one control subject where comparable studies have been made
Intramuscular nerves and nerve terminals
The pattern of branching of the intramuscular nerves and (Control 3). In summary, the anatomical studies show that the reduced presynaptic terminals was studied in silver impregnated preparations from control and AChR-deficiency patients abundance of AChRs in the AChR-deficiency patients is associated with increased branching of the preterminal axons (examples in Fig. 3 , top panels). In only one of the four AChR-deficiency patients (AChRD 2) was there evidence of and elongated neuromuscular junctions which, though of normal overall area, have moderately reduced postsynaptic increased collateral innervation or sprouting (see also Table  3 ). However, in all four AChR-deficiency cases the folding. preterminal axons were often much more highly branched than normal, several branches innervating each neuromuscular junction. In addition, the presynaptic terminals tended to be Immunolabelling more elongated than normal with occasional short lateral Immunolabelling studies of postsynaptic proteins that might sprouts, some with synaptic boutons.
have an influence on AChR distribution or abundance were made on unfixed frozen sections. In the absence of detectable α-bungarotoxin binding, FITC-DBA, which binds to a
AChE distribution
component of the synaptic basal lamina (Sanes and Cheney, Neuromuscular junctions in control subjects and all four 1982), was used to indicate the position of neuromuscular AChR-deficiency patients were clearly labelled by a junctions. Clear labelling of neuromuscular junctions with histochemical reaction for demonstrating AChE activity (e.g.
FITC-DBA was found in biopsy samples from all subjects. see Fig. 3 
, bottom panels). A number of patients previously
All antibodies were detected with TMRITC-labelled second described with congenital AChR deficiency were found to antibodies. Typical examples of labelling are shown in Fig.  have had elongated neuromuscular junctions consisting of 5 and the patterns of labelling are summarized in Table 5 . numerous separate clusters of high AChE activity (Vincent et al., 1981; Shillito et al., 1993) . This was also true of the AChR-deficiency patients described here. The mean length
Rapsyn of neuromuscular junctions in Patient AChRD 1 was
Labelling for rapsyn, known to be closely associated with significantly greater than in control samples from vastus AChRs and to be essential for AChR clustering (Froehner, lateralis (Table 3) while the lengths of neuromuscular 1993), was strong at all neuromuscular junctions in all junctions in Patients AChRD 2-4 were greater than in controls and three of the four AChR-deficiency patients. In comparable control material from previously reported Patient AChRD 2, rapsyn labelling was detectable but intercostal muscle biopsies (Vincent et al., 1981) . In contrast, appeared weaker than normal (data not shown). the total area occupied by the AChE reaction product was highly variable and was not significantly larger than that found in control samples (Table 3) .
Utrophin
Labelling for utrophin was strong at all neuromuscular junctions of control subjects but was not detectable (or only
Ultrastructure
The ultrastructure of the neuromuscular junctions in each of barely detectable) at neuromuscular junctions in any of the four AChR-deficiency patients. This was true with antibodies the AChR-deficiency samples was qualitatively normal, in that all the main features of the nerve terminals, Schwann to both N-terminal (DRP1/20C5) and C-terminal (DRP1/ 12B6, MANCHO7) epitopes of utrophin (see below). cells, basal lamina and postsynaptic apparatus were present (7) 15.9 Ϯ 13.6 (7) 1.12 Ϯ 0.10 (7) 31.9 Ϯ 3.8 (7) 180.7 Ϯ 50.7 (7) Intercostal ND ND ND 24.8 Ϯ 3.2 (7) ‡ ND Sprouts ϭ fraction of neuromuscular junctions where preterminal or ultraterminal sprouts were seen in silver-impregnated preparations (%); Collaterals ϭ fraction of neuromuscular junctions which were innervated by a branch of an axon which originated after the parent axon had left the intramuscular nerve bundle (%); FTIR ϭ functional terminal innervation ratio (defined in Methods); ChE area ϭ mean area (µm 2 ) of region occupied by histochemical reaction product resulting from ChE activity; ChE length ϭ mean length (µm), along muscle fibre axis, of region occupied by histochemical reaction product resulting from ChE activity; ND ϭ not done. *Values for these individual subjects are means Ϯ SDs (and numbers of neuromuscular junctions). † Values for pooled controls are means Ϯ SDs (and numbers of patients). ‡ Values derived from data in Ito et al. (1978) , assuming a sarcomere length of 3.3 µm.
role in clustering of AChRs. However, the converse may be β-Dystroglycan true; that a high concentration of AChRs is necessary for This transmembrane protein is a member of the complex of utrophin to become localized at the neuromuscular junction. dystrophin-associated proteins and contains the site that links
To test the latter hypothesis, we investigated utrophin labelling dystrophin (or utrophin) to this complex (Tinsley et al., in patients in whom AChR abundance is reduced for a 1994). Strong labelling for β-dystroglycan was present in completely different reason; those with acquired autoimmune the extrajunctional region and was more intense at all myasthenia gravis. neuromuscular junctions studied in AChR-deficiency patients
In each of three patients with myasthenia gravis, the and controls.
intensity of labelling of utrophin at the neuromuscular junction was reduced, approximately in parallel with that of the AChRs (Fig. 6 , Table 5 ). The intensity of labelling of all Dystrophin the other proteins studied appeared normal. Labelling for dystrophin is normally present at the surface of each muscle fibre in the extrajunctional region and, at higher intensity, at the neuromuscular junctions. This pattern of labelling was seen in each of the AChR-deficiency patients
Quantification of AChR and utrophin labelling
In an effort to compare our impressions of the intensity of and in all the controls examined.
AChR, utrophin and dystrophin labelling in a more objective way, we recorded fluorescence images of neuromuscular junctions in frozen sections using a digital cooled CCD
β-Spectrin
The pattern of labelling for β-spectrin with antibody RBC2/ camera. From images of FITC-DBA labelled neuromuscular junctions, the area of high intensity labelling and the mean 5C4 is normally similar to that for dystrophin in the extrajunctional and junctional regions of adult mammalian intensity of labelling within that area were determined (see Methods). The intensity of antibody labelling within the same muscle. This normal pattern was also seen in each AChRdeficiency patient and in each of the controls studied.
area was then determined from images of TMRITC-secondary antibody labelled neuromuscular junctions. Thus, in summary, in all the AChR-deficiency patients, the intensity of labelling for utrophin is profoundly weaker
The intensity of FITC-DBA labelling was very similar in neuromuscular junctions from controls, AChR-deficiency than normal while that for a number of related proteins is not.
and myasthenia gravis patients (data not shown). However, the area of the region occupied by high intensity labelling was less at neuromuscular junctions from AChR-deficiency (12.1 Ϯ 7.8 µm 2 ) and myasthenia gravis (14.9 Ϯ 3.7 µm 2 )
Myasthenia gravis
The reduced labelling of utrophin at the neuromuscular patients than in controls (18.5 Ϯ 7.8 µm 2 ). In each of the three AChR-deficiency patients studied, the intensity of junction in patients with inherited AChR deficiencies would be consistent with a primary defect in utrophin abundance labelling of the α-and ε-AChR subunits was~15-20% of the mean value of the three controls (Fig. 7A ). In the three or structure in these patients if utrophin plays an important Fig. 4 Postsynaptic folding appears reduced at neuromuscular junctions of AChR-deficiency patients relative to controls. This is confirmed by measurements presented in Table 4 . Electron micrographs of neuromuscular junctions of control subjects in vastus lateralis (Control 38 from Slater et al., 1992) and the intercostal muscle (Control 3), and of neuromuscular junctions of AChR-deficiency patients in vastus lateralis (Patient AChRD 1) and the intercostal muscle (Patient AChRD 4). myasthenia gravis patients, AChR labelling was greater than less than in controls but more than in AChR-deficiency patients, with the most intense labelling seen in Patient MG that in the AChR-deficiency patients but less than that in the controls.
2, in which the most intense immunolabelling of AChRs was also seen. Dystrophin labelling was somewhat less intense The mean intensity of utrophin labelling in the AChRdeficiency patients by the antibody to the peptide at the Nin myasthenia gravis patients than in controls, but clearly less reduced than that of utrophin. terminus (DRP3/20C5) was Ͻ10% of that in the controls (Fig. 7B) . Very similar results were obtained with the two
The foregoing analysis suggests a positive correlation between the intensity of utrophin and AChR labelling. This antibodies to the C-terminus (DRP1/12B6 and MANCHO 7, data not shown). By contrast, the intensity of labelling is confirmed in Fig. 8 , where the relative intensity of utrophin labelling by antibody DRP3/20C5 has been shown as a for dystrophin at the neuromuscular junctions of AChRdeficiency patients was ജ50% of that in controls. In the function of ε-AChR labelling. The correlation between the two variables is highly significant (r ϭ 0.91, P Ͻ 0.001). myasthenia gravis patients, utrophin labelling was clearly (9) 39.9 Ϯ 22.8 (9) 3.17 Ϯ 0.88 (9) 0.97 Ϯ 1.04 (9) MG 1* Intercostal 1.69 Ϯ 1.11 (7) 17.8 Ϯ 9.5 (7) 3.14 Ϯ 0.74 (7) 1.00 Ϯ 0.67 (7) Cont 1* Vastus lateralis 0.74 Ϯ 0.66 (4) 34.9 Ϯ 3.2 (4) 8.18 Ϯ 3.34 (4) 2.09 Ϯ 0.15 (4) Cont 3* Intercostal 2.34 Ϯ 1.38 (9) 37.9 Ϯ 11.4 (9) 5.71 Ϯ 1.50 (9) 1.48 Ϯ 0.54 (9) Controls † Vastus lateralis 1.63 Ϯ 0.69 (7) 40.8 Ϯ 9.4 (7) 8.79 Ϯ 2.16 (7) 2.20 Ϯ 0.15 (4) NTA ϭ mean area (µm 2 ) of individual nerve terminal profiles; Occupancy ϭ fraction (%) of postsynaptic length, measured along the tops of the folds, which is in close contact with a nerve terminal; Fold Index ϭ the ratio of the total length of postsynaptic membrane including the folds, to the length of the postsynaptic specialization measured along the top of the folds (see Slater et al., 1992) ; Fold Frequency ϭ mean number of fold openings/µm of postsynaptic membrane in contact with nerve terminal (µm -1 ). *Values for patients are means Ϯ SDs (and numbers of neuromuscular junctions). † Values for pooled controls are means Ϯ SDs (and numbers of patients).
No significant correlation between dystrophin and AChR of the protein as a whole rather than simply an abnormality labelling was found (r ϭ 0.47, P Ͼ 0.1).
of the α-bungarotoxin or ACh binding site or loss of a single AChR subunit. It is clear that the loss of AChRs is sufficient to explain the impairment of neuromuscular transmission and Discussion the clinical weakness of these patients. Our main finding is that each of four patients with congenital
In addition to the loss of AChRs, the neuromuscular AChR deficiency had a greatly reduced abundance of utrophin junctions of these four AChR-deficiency patients have in the postsynaptic cytoplasm, as detected by three different morphological features similar to those of some (Vincent monoclonal antibodies. We also found a reduction of utrophin et al., 1981) , but not all (Engel et al., 1990 ) previously abundance in each of three patients with an acquired AChR reported cases with AChR deficiency. In each of them, the deficiency, myasthenia gravis. In both conditions, the total area of synaptic contact was normal, or moderately deficiency of utrophin is specific, in that several other increased, but the length of the neuromuscular junction was proteins of the postsynaptic cytoskeleton persist in substantial significantly greater than normal. This is often associated amounts. These results suggest that the loss of utrophin in with the presence of a number of well-separated regions of both groups of patients may be a consequence of the reduced differentiated postsynaptic membrane. Studies of the nerve abundance of AChRs rather than vice versa. A modest terminals showed that this results from an abnormal pattern reduction in postsynaptic folding was also found in both of terminal branching of the motor axons, which often appear groups of patients.
to have wandered along the surface of the muscle fibre, making numerous synaptic contacts. Similar abnormalities have been seen in such diverse conditions as vitamin B 12
The AChR-deficiency patients are similar to deficiency, dystrophia myotonica (Coërs and Woolf, 1959) , botulinum intoxication (Duchen and Strich, 1968) and some previously described postsynaptic block (Holland and Brown, 1980) . In the present The four AChR-deficiency patients studied here have a context, it seems most likely that the response of the number of similarities with several patients described muscle fibre to 'partial functional denervation' has stimulated previously in whom a reduction of AChRs was a prominent terminal sprouting of the motor axon (Brown et al., 1981 ) feature (Vincent et al., 1981 Shillito et al., 1993) .
followed by the formation of new zones of postsynaptic Each was the offspring of a marriage between cousins, each specialization. Since there was little indication of ongoing had fatiguable muscle weakness detected during the first year sprouting in the biopsy samples, it is possible that an of life associated with clinical electrophysiological evidence improvement in function brought about by prolonged of impaired neuromuscular transmission, and each was antianticholinesterase therapy may have suppressed this process. AChR negative. These features are characteristic of a A new finding of this study is a reduction in postsynaptic congenital myasthenic syndrome. In each case, studies of folding in AChR-deficiency patients. In the case of Patient biopsy samples revealed greatly reduced MEPP amplitude AChRD 1 (age 8 years) this may be due, in part, to immaturity and a reduction of AChR labelling to a level that, in some of the neuromuscular junction, since folding at human cases, was undetectable. This reduction of AChR labelling neuromuscular junctions is known to increase throughout life was confirmed in this study with subunit-specific antibodies as well as α-bungarotoxin, indicating that it represented loss (Arizono et al., 1984; Wokke et al., 1990) . It is believed that 
Dystrophin was detected with DYS1/6C5, and utrophin with DRP3/20C5. The symbols are explained in Methods. ND ϭ not done.
Fig. 7
Quantification of labelling for AChRs and utrophin/dystrophin. The relative intensity of fluorescent labelling at neuromuscular junctions was quantified in frozen sections as described in Methods. The mean of the control values for each label was taken as 100% and other samples were expressed as a percentage of that intensity. (A) α-and ε-AChR antibodies (black and white bars, respectively). The level of AChRs is greatly reduced relative to controls in AChR-deficiency patients and somewhat less so in myasthenia gravis patients. (B) Labelling for utrophin (antibody DRP3/20C5) and dystrophin (black and white bars, respectively). Utrophin is greatly reduced in all three AChR-deficiency patients and somewhat less so in the myasthenia gravis cases. Dystrophin labelling was only slightly lower in the AChR-deficiency and myasthenia gravis patients than in the controls. Details of quantification described in Methods.
Postsynaptic proteins at neuromuscular junctions in AChR-deficiency and myasthenia gravis patients
Numerous factors may influence the development and maintenance of the very high concentration of AChRs at the neuromuscular junction. One of these is likely to be the interaction of AChRs with the complex of membrane and cytoskeletal proteins associated with the postsynaptic membrane of the muscle fibre. The immunocytochemical studies reported here show that a number of these proteins are present in AChR-deficiency patients. In particular, strong labelling for rapsyn was present at the neuromuscular junctions of all four patients, although apparently reduced in one (Patient AChRD 2). While it may seem surprising that rapsyn remains clustered at the neuromuscular junction in the absence of most of the AChRs, previous expression studies using cultured cells have shown that rapsyn can form surface clusters in the absence of AChRs, and such clusters (Froehner, 1993) .
eight subjects for which data are available (see Fig. 7 ). There is a
The most striking change in the protein composition of highly significant correlation between the intensity of labelling for the postsynaptic region in the AChR-deficiency patients is the two proteins [r(7) ϭ 0.91, P Ͻ 0.001].
the essentially complete absence of utrophin. The reduction of utrophin labelling was confirmed quantitatively using three the folds and the voltage-gated sodium channels within the different antibodies, recognizing epitopes at both the N-and membrane in their depths, serve to amplify the effects of C-termini of the protein. This argues for the absence of ACh released from the nerve (Vautrin and Mambrini, 1989;  utrophin rather than the presence of a truncated or otherwise Slater et al., 1992; Martin, 1994; Wood and Slater, 1995, abnormal form to which the antibodies fail to bind. The 1997). This effect is likely to be particularly important in function of utrophin is not known. It is normally very man, where the nerve terminal is small and the folding precisely co-localized with AChRs both in the adult (Bewick extensive. As a result, any substantial reduction in folding et al., 1992) and throughout development (Phillips et al. , and of the sodium channels within the folds would be 1993; Bewick et al., 1996) and this has led to the suggestion likely to compromise effective neuromuscular transmission.
that it stabilizes AChR clusters during development (Phillips Reduced folding has been seen in a number of patients with et al., 1993) . However, recent studies of utrophin-deficient various forms of congenital myasthenic syndrome (Smit mice show that utrophin is not essential for neuromuscular et al., 1987; Slater et al., 1995) and may be a rather general junction formation or for precise localization of AChRs at pathological response of the neuromuscular junction (see the neuromuscular junction (Deconinck et al., 1997; Grady below) . By contrast, there is some evidence of increased et al., 1997). postsynaptic folding in Lambert-Eaton myasthenic syndrome Utrophin, like dystrophin, is generally believed to be (Engel and Santa, 1971) . Little is known about the mechanism localized at the membrane by virtue of its binding to β-of fold formation or the mechanisms by which the distinctive dystroglycan (Tinsley et al., 1994) . Since β-dystroglycan localizations of the AChRs and voltage-gated sodium labelling is present with near-normal intensity at channels within them are maintained. neuromuscular junctions of AChR-deficiency patients, some On the basis of the family history of these patients, it is factor other than the abundance of β-dystroglycan is likely likely that the disorder in each case was inherited as an to account for the reduction in utrophin. One possibility is autosomal recessive trait. The parents of each patient, though that the reduced abundance of utrophin is a secondary unaffected themselves, were close relatives and in two cases, consequence of the loss of AChRs. It was to test this idea siblings were also affected. As yet, however, the underlying that we investigated the profile of postsynaptic proteins at genetic abnormalities remain unknown and it is therefore neuromuscular junctions in three patients with myasthenia unclear whether these patients have the same or different gravis. The intensity of AChR labelling in the myasthenia genetic defects. Nor is it clear whether the defect is in the gravis cases was less than in controls but more than in gene for utrophin, AChRs, or some other protein. The
AChR-deficiency samples and this was roughly parallelled prolonged decay time of the EPC in Patient AChRD 1 is by the intensity of utrophin labelling (Fig. 8) . The loss of consistent with a modification of one or more subunits of AChRs in myasthenia gravis is believed to result from a the AChR (see Vincent et al., 1997) et al., 1977) . In the myasthenia gravis patients, as in those with in localizing AChRs at the neuromuscular junction. The AChR deficiency, the loss of utrophin from the neuromuscular results of this study suggest an alternative view. In two junction is relatively specific, with rapsyn, β-dystroglycan, groups of patients with very different pathological processes, dystrophin and β-spectrin generally remaining strongly AChR deficiency at the neuromuscular junction is associated labelled. This suggests that the processes that cause the with a specific reduction in the abundance of utrophin in the reduction of AChRs in myasthenia gravis, though presumably underlying cytoskeleton. This suggests that AChRs may different from those operating in AChR deficiency, also cause be required for utrophin localization at the neuromuscular a relatively specific loss of utrophin from the postsynaptic junction. By contrast, the presence, at the neuromuscular cytoskeleton.
junction, of rapsyn and several other postsynaptic proteins This study thus suggests a link between the loss of AChRs in the face of greatly diminished AChR abundance suggests and that of utrophin. Such a link might come about if the that the concentration and maintenance of these proteins high concentration of utrophin at the membrane depends on at the neuromuscular junction is independent of AChR the presence of AChRs. Little is known about how AChRs accumulation. Finally, the reduction of folding at the interact with the proteins of the utrophin/dystrophin neuromuscular junctions in cases of AChR deficiency complex. One possibility, suggested by our results, is that suggests that AChRs and/or utrophin may play some part in utrophin is more directly bound to AChRs than has previously the formation or maintenance of postsynaptic folds. been thought. While rapsyn seems likely to play a key role in any interaction between AChRs and the cytoskeleton, the details of rapsyn's interaction with AChRs are also poorly
